INTRODUCTION: (1) Since 2009 China had implemented national essential drug system, and issued first and second edition of NEDL (National Essential Drugs List) respectively in 2009 and 2013, which respectively covered 307 drugs and 520 drugs. (2) With development of Chinese healthcare reform, planning low-priced drug policy and adjusted essential drug system will impact on drug access. OBJECTIVES: To describe Chinese policies’ development for promoting drug access, analyze the policies’ impact and potential lacks. METHODS: Through collecting relevant policies from national departments and 31 provinces, apply descriptive statistics and comparison to summarize these policies’ impact. RESULTS: (1) On May 2013 China NHFPC had released the second edition of NEDL, which increased to 520 drugs and allowed all provinces to implement after appropriate addition. Until the end of February 2014, nine provinces in China had supplemented average 251 drugs (average 121 western medicines and 130 TCM) on the basis of 520 drugs. The most was 535 in Xinjiang and the least is 57 in Gansu. (2) Meanwhile, China NDRC was planning to introduce low-priced drug list covering 890 drugs, the price control of which will be released if average daily cost is less than 3 RMB for western drugs or 5 RMB for TCM. (3) On February 27, 2014 Guangdong province had released “low-priced drugs list of non-essential drugs” including 1103 drugs, then plus essential drugs in the province, relatively cheap drugs that patients could afford are theoretically up to 1902. CONCLUSIONS: (1) These two policies had provided quantitatively safeguard for patients access to relatively cheap drugs close to 2,000. (2) Chinese “parallel development” policy for TCM and Western Medicine will be insisted on for a long term. (3) It needs more scientific mechanism designed to avoid the lacks of“double envelop”tendering and distortion of doctors’ income.